Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

61. High- versus low-intensity interventions for perinatal depression delivered by non-specialist primary maternal care providers in Nigeria: cluster randomised controlled trial (the EXPONATE trial) (Abstract)

High- versus low-intensity interventions for perinatal depression delivered by non-specialist primary maternal care providers in Nigeria: cluster randomised controlled trial (the EXPONATE trial) Contextually appropriate interventions delivered by primary maternal care providers (PMCPs) might be effective in reducing the treatment gap for perinatal depression.To compare high-intensity treatment (HIT) with low-intensity treatment (LIT) for perinatal depression.Cluster randomised clinical trial (...) , conducted in Ibadan, Nigeria between 18 June 2013 and 11 December 2015 in 29 maternal care clinics allocated by computed-generated random sequence (15 HIT; 14 LIT). Interventions were delivered individually to antenatal women with DSM-IV (1994) major depression by trained PMCPs. LIT consisted of the basic psychosocial treatment specifications in the World Health Organization Mental Health Gap Action Programme - Intervention Guide. HIT comprised LIT plus eight weekly problem-solving therapy sessions

2019 EvidenceUpdates

62. Adverse Effects of Pharmacological Treatments of Major Depression in Older Adults

Adverse Effects of Pharmacological Treatments of Major Depression in Older Adults Adverse Effects of Pharmacological Treatments of Major Depression in Older Adults Comparative Effectiveness Review Number 215 RComparative Effectiveness Review Number 215 Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract (...) No. 290-2015-00012-I Prepared by: University of Connecticut Evidence-based Practice Center Storrs, CT Investigators: Diana M. Sobieraj, Pharm.D. William L. Baker, Pharm.D. Brandon K. Martinez, Pharm.D. Adrian V. Hernandez, M.D., Ph.D. Craig I. Coleman, Pharm.D. Joseph S. Ross, M.D., M.H.S. Karina M. Berg, M.D., M.S. David C. Steffens, M.D. AHRQ Publication No. 19-EHC011-EF March 2019 ii Key Messages Purpose of Review To assess adverse events of antidepressants in the treatment of major depressive

2019 Effective Health Care Program (AHRQ)

63. Depression in primary care: part 1-screening and diagnosis. Full Text available with Trip Pro

Depression in primary care: part 1-screening and diagnosis. Depression is a common and heterogeneous condition with a chronic and recurrent natural course that is frequently seen in the primary care setting. Primary care providers play a central role in managing depression and concurrent physical comorbidities, and they face challenges in diagnosing and treating the condition. In this two part series, we review the evidence available to help to guide primary care providers and practices (...) to recognize and manage depression. In this first of two reviews, we outline an approach to screening and diagnosing depression in primary care that evaluates current evidence based guidelines and applies the recommendations to clinical practice. The second review presents an evidence based approach to the treatment of depression in primary care, detailing the recommended lifestyle, drug, and psychological interventions at the individual level. It also highlights strategies that are being adopted

2019 BMJ

64. Depression in primary care: part 2-management. Full Text available with Trip Pro

Depression in primary care: part 2-management. Depression is a common and heterogeneous condition with a chronic and recurrent natural course that is frequently seen in the primary care setting. Primary care providers play a central role in managing depression and concurrent physical comorbidities, and they face challenges in diagnosing and treating the condition. In this two part series, we review the evidence available to help to guide primary care providers and practices to recognize (...) and manage depression. The first review outlined an approach to screening and diagnosing depression in primary care. This second review presents an evidence based approach to the treatment of depression in primary care, detailing the recommended lifestyle, drug, and psychological interventions at the individual level. It also highlights strategies that are being adopted at an organizational level to manage depression more effectively in primary care.Published by the BMJ Publishing Group Limited

2019 BMJ

65. Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice

Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search for this keyword Source User menu Sections Sign up for highlighting editor-chosen studies (...) with the greatest impact on clinical care. This policy is a revision of the policy in Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice Jason Rafferty , Gerri Mattson , Marian F. Earls , Michael W. Yogman , COMMITTEE ON PSYCHOSOCIAL ASPECTS OF CHILD AND FAMILY HEALTH Abstract Perinatal depression is the most common obstetric complication in the United States, with prevalence rates of 15% to 20% among new mothers. Untreated, it can adversly affect the well-being of children

2019 American Academy of Pediatrics

66. Randomized Trial of a Tailored Cognitive Behavioral Intervention in Type 2 Diabetes With Comorbid Depressive and/or Regimen-Related Distress Symptoms: 12-Month Outcomes From COMRADE (Abstract)

Randomized Trial of a Tailored Cognitive Behavioral Intervention in Type 2 Diabetes With Comorbid Depressive and/or Regimen-Related Distress Symptoms: 12-Month Outcomes From COMRADE This study evaluated the effect of cognitive behavioral therapy (CBT) plus lifestyle counseling in primary care on hemoglobin A1c (HbA1c) in rural adult patients with type 2 diabetes (T2D) and comorbid depressive or regimen-related distress (RRD) symptoms.This study was a randomized controlled trial of a 16-session (...) severity-tailored CBT plus lifestyle counseling intervention compared with usual care. Outcomes included changes in HbA1c, RRD, depressive symptoms, self-care behaviors, and medication adherence across 12 months.Patients included 139 diverse, rural adults (mean age 52.6 ± 9.5 years; 72% black; BMI 37.0 ± 9.0 kg/m2) with T2D (mean HbA1c 9.6% [81 mmol/mol] ± 2.0%) and comorbid depressive or distress symptoms. Using intent-to-treat analyses, patients in the intervention experienced marginally significant

2019 EvidenceUpdates

67. Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown.To examine the effect of 2 nutritional strategies (multinutrient supplementation, food-related behavioral activation therapy (...) ) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms.This multicenter 2 × 2 factorial randomized clinical trial included overweight adults (body mass index, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores ≥5) and no MDD episode in the past 6 months from 4 European countries. A total of 1025 adults were randomized (July 30, 2015-October 12, 2016) and followed up for 1 year (October 13, 2017).Daily multinutrient

2019 JAMA Controlled trial quality: predicted high

68. Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. Coexisting obesity and depression exacerbate morbidity and disability, but effective treatments remain elusive.To test the hypothesis that an integrated collaborative care intervention would significantly improve both obesity and depression at 12 months compared with usual care.The Research (...) control group (n = 205) received medical care from their personal physicians as usual, received information on routine services for obesity and depression at their clinic, and received wireless physical activity trackers. Intervention participants also received a 12-month intervention that integrated a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression and, if indicated, antidepressant medications.The co-primary outcome measures were BMI

2019 JAMA Controlled trial quality: predicted high

69. Effectiveness of psychological treatments for depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal Full Text available with Trip Pro

Effectiveness of psychological treatments for depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal Evidence shows benefits of psychological treatments in low-resource countries, yet few government health systems include psychological services.AimEvaluating the clinical value of adding psychological treatments, delivered by community-based counsellors, to primary care-based mental health (...) services for depression and alcohol use disorder (AUD), as recommended by the Mental Health Gap Action Programme (mhGAP).Two randomised controlled trials, separately for depression and AUD, were carried out. Participants were randomly allocated (1:1) to mental healthcare delivered by mhGAP-trained primary care workers (psychoeducation and psychotropic medicines when indicated), or the same services plus individual psychological treatments (Healthy Activity Program for depression and Counselling

2019 EvidenceUpdates

70. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders

Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders Final Recommendation Health Quality Ontario, under the guidance of the Ontario (...) Health Technology Advisory Committee, recommends publicly funding guided internet-delivered cognitive behavioural therapy for mild to moderate major depression and anxiety disorders Cognitive behavioural therapy (or “CBT”) is a form of psychotherapy that has proven effective in treating major depression and anxiety disorders. However, it can often be difficult for people to access this therapy because of long wait times, the cost of sessions, and travel time to get to sessions. Cognitive behavioural

2019 Health Quality Ontario

71. Vagus Nerve Stimulation for chronic major depressive episodes

Vagus Nerve Stimulation for chronic major depressive episodes Public Summary Document Application No. 1491 - Vagus Nerve Stimulation (VNS) for chronic major depressive episodes Applicant: LivaNova Australia Pty Ltd Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefit Schedule (MBS) listing for Vagus Nerve (...) Stimulation (VNS) for chronic major depressive episodes was received from LivaNova Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC did not support MBS funding of VNS for chronic major depressive episodes. MSAC accepted that there was a clinical need for more treatment options for this patient population. However, MSAC had concerns

2019 Medical Services Advisory Committee

72. Bright light therapy for depression in Parkinson disease: A randomized controlled trial (Abstract)

Bright light therapy for depression in Parkinson disease: A randomized controlled trial To assess the efficacy of bright light therapy (BLT) in reducing depressive symptoms in patients with Parkinson disease (PD) and major depressive disorder (MDD) compared to a control light.In this double-blind controlled trial, we randomized patients with PD and MDD to treatment with BLT (±10,000 lux) or a control light (±200 lux). Participants were treated for 3 months, followed by a 6-month naturalistic (...) follow-up. The primary outcome of the study was the Hamilton Depression Rating Scale (HDRS) score. Secondary outcomes were objective and subjective sleep measures and salivary melatonin and cortisol concentrations. Assessments were repeated halfway, at the end of treatment, and 1, 3, and 6 months after treatment. Data were analyzed with a linear mixed-model analysis.We enrolled 83 participants. HDRS scores decreased in both groups without a significant between-group difference at the end of treatment

2019 EvidenceUpdates

73. Effects of Light Therapy on Mood and Insulin Sensitivity in Patients With Type 2 Diabetes and Depression: Results From a Randomized Placebo-Controlled Trial (Abstract)

Effects of Light Therapy on Mood and Insulin Sensitivity in Patients With Type 2 Diabetes and Depression: Results From a Randomized Placebo-Controlled Trial Depression is common in patients with type 2 diabetes and adversely affects quality of life and diabetes outcomes. We assessed whether light therapy, an antidepressant, improves mood and insulin sensitivity in patients with depression and type 2 diabetes.This randomized, double-blind, placebo-controlled trial included 83 patients (...) with depression and type 2 diabetes. The intervention comprised 4 weeks of light therapy (10,000 lux) or placebo light therapy daily at home. Primary outcomes included depressive symptoms (Inventory of Depressive Symptomatology [IDS]) and insulin sensitivity (M-value derived from the results of a hyperinsulinemic-euglycemic clamp). Secondary outcomes were related psychological and glucometabolic measures.Intention-to-treat analysis showed that light therapy was not superior to placebo in reducing depressive

2019 EvidenceUpdates

74. Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial. (Abstract)

Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial. Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited.To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (...) (phase 2) for treating depression in patients receiving hemodialysis.Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343).41 dialysis facilities in 3 U.S. metropolitan areas.Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2.Engagement interview versus control visit (phase 1) and 12 weeks

2019 Annals of Internal Medicine Controlled trial quality: predicted high

75. Management of perinatal depression with non-drug interventions. Full Text available with Trip Pro

Management of perinatal depression with non-drug interventions. Perinatal depression is a common disorder that has been associated with serious risks to mother and child. Recently, screening for depression in pregnant and postpartum women has increased, as has the development of new psychotherapy and non-drug treatment modalities. Matching patients to treatments can be challenging, and although research into personalized treatment of major depression in the general population has increased (...) , no published guidelines focus on personalized treatment approaches to perinatal depression. In particular, guidelines on non-drug treatments are lacking. This review summarizes the evidence on personalized non-drug treatment of perinatal depression, how to incorporate patients' preferences, novel treatments under investigation, and the potential role of biomarkers in matching patients to treatment. The review provides recommendations for future research in personalized care of perinatal

2019 BMJ

76. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. Perinatal depression, which is the occurrence of a depressive disorder during pregnancy or following childbirth, affects as many as 1 in 7 women and is one of the most common complications of pregnancy and the postpartum period. It is well established that perinatal depression can result in adverse short- and long-term effects on both the woman and child.To issue a new US Preventive (...) Services Task Force (USPSTF) recommendation on interventions to prevent perinatal depression.The USPSTF reviewed the evidence on the benefits and harms of preventive interventions for perinatal depression in pregnant or postpartum women or their children. The USPSTF reviewed contextual information on the accuracy of tools used to identify women at increased risk of perinatal depression and the most effective timing for preventive interventions. Interventions reviewed included counseling, health system

2019 JAMA

77. Postnatal depression

Postnatal depression Postnatal depression - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Postnatal depression Last reviewed: February 2019 Last updated: February 2019 Summary Refers to the development of a depressive illness following childbirth and may form part of a unipolar or, less frequently, a bipolar illness. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) does not recognise (...) postnatal depression as a separate diagnosis; rather, patients must meet the criteria for a major depressive episode and the criteria for the perinatal-onset specifier. The definition according to DSM-5 is, therefore, a major depressive episode with an onset in pregnancy or within 4 weeks of delivery. However there is no established consensus as to the length of postnatal period, and some authorities define postnatal depression as occurring within the first 12 months after delivery. Aetiology is poorly

2019 BMJ Best Practice

78. Standardized Library of Depression Outcome Measures

Standardized Library of Depression Outcome Measures Standardized Library of Depression Outcome Measures | Effective Health Care Program Search Effective Health Care website Submit search Toggle navigation Select site to search Search Effective Health Care website Submit search Standardized Library of Depression Outcome Measures Michelle B. Leavy, M.P.H. Fang Li, MD, M.S. * OM1 On behalf of the Outcome Measures Framework (OMF) Depression Workgroup. Abstract Significant variation exists in both (...) conditions; it is intended to serve as a content model for developing harmonized outcome measures for specific clinical areas. AHRQ assessed the feasibility of using the OMF to develop standardized libraries of outcome measures in five clinical areas: atrial fibrillation, asthma, depression, lung cancer, and lumbar spondylolisthesis. These clinical areas represent diverse populations and care settings, different treatment modalities, and varying levels of harmonization. For each clinical area

2019 Effective Health Care Program (AHRQ)

79. The depressing evidence for antidepressants in the elderly

The depressing evidence for antidepressants in the elderly Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 5,000 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca February 4 (...) , 2019 The depressing evidence for antidepressants in the elderly Clinical Question: How effective are antidepressants for treating depression in the elderly? Bottom Line: The efficacy of antidepressants in the elderly is inconsistent and may decrease as patients age. From 80% to 40% of elderly patients will recover with antidepressants, with some studies showing no difference from placebo response rates. Harms of antidepressants are common, with ~20% stopping due to adverse effects. Evidence: • 5

2019 Tools for Practice

80. Patient-controlled intravenous tramadol versus patient-controlled intravenous hydromorphone for analgesia after secondary cesarean delivery: a randomized controlled trial to compare analgesic, anti-anxiety and anti-depression effects Full Text available with Trip Pro

Patient-controlled intravenous tramadol versus patient-controlled intravenous hydromorphone for analgesia after secondary cesarean delivery: a randomized controlled trial to compare analgesic, anti-anxiety and anti-depression effects This study aimed to compare the postoperative analgesic effects of tramadol and hydromorphone for secondary cesarean delivery (CD) as well as their anti-anxiety and anti-depression properties.A total of 106 patients receiving secondary CD under spinal anesthesia (...) were randomly allocated to the tramadol group (n=53) and the hydromorphone group (n=53). Each group received patient-controlled intravenous analgesia using flurbiprofen 4 mg/kg combined with tramadol (4 mg/kg) or hydromorphone (0.04 mg/kg) immediately after the surgery. Postoperative pain numerical rating scale (NRS) for incision and visceral pain, hospital anxiety and depression scale (HADS), early walking time and length of hospital stay were assessed.Patients in the tramadol and hydromorphone

2019 EvidenceUpdates